Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on N Arylation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102863387A reveals a copper-catalyzed route for imidazolium salts, offering high yields and mild conditions for reliable ionic liquid and catalyst precursor manufacturing.
Novel nickel-catalyzed route offers air-stable efficiency for pharmaceutical intermediates, reducing cost and improving supply chain reliability for global buyers seeking scalable solutions.
Patent CN114315536A reveals a metal-free method for synthesizing axial chiral diarylethenes with high enantioselectivity, offering significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN112645909B details air-stable nickel catalysis for alpha-benzylbenzofuran. Enhances supply chain reliability and reduces manufacturing costs for pharmaceutical intermediates.
Breakthrough aqueous-phase C-N coupling technology enabling cost-effective production of complex pharmaceutical intermediates with enhanced supply chain reliability.
Patent CN112645909B introduces air-stable nickel catalyst for alpha-benzylbenzofuran synthesis enhancing substrate scope reducing manufacturing costs through simplified process with improved supply chain reliability
Patent CN106187656B enables >99% selective monoarylation under mild conditions, reducing costs and lead times for high-purity fine chemicals.
Overcome high costs and safety risks in 2-chloro-4-fluorobenzoic acid production. Our new Meerwein arylation method eliminates noble metals, reduces waste, and achieves >80% yield for saflufenacil synthesis.
Discover a novel nickel-catalyzed method for 2-phenyl-5-benzyl-imidazo[1,2-a]pyridine synthesis with high yields and air-stable catalysts. Reduce production costs and supply chain risks for your pharmaceutical intermediates.
Discover how photocatalytic N-alpha arylation eliminates HAT reagents, reduces costs, and achieves 99% purity for pharmaceutical intermediates. Scale to 100 MT/annual with CDMO expertise.